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ABSTRACT 
 
Background: Drug resistance is a challenge for the global control of tuberculosis. We 
examined mortality in tuberculosis patients from high-burden countries, according to 
concordance or discordance of results from drug susceptibility testing (DST) done 
locally and in a reference laboratory. 
Methods: We collected Mycobacterium tuberculosis isolates from adult patients in Côte 
d’Ivoire, Democratic Republic of the Congo, Kenya, Nigeria, South Africa, Peru, and 
Thailand, stratified by HIV status and tuberculosis drug resistance. Molecular or 
phenotypic drug susceptibility testing (DST) was done locally and at the Swiss 
tuberculosis reference laboratory. We examined mortality during treatment according to 
DST results and treatment adequacy in logistic regression models adjusting for sex, 
age, sputum microscopy and HIV status. 
Findings: 634 tuberculosis patients were included; median age was 33.2 years, 239 
(37.7%) were female, 272 (42.9%) HIV-positive and 69 (10.9%) patients died. Based on 
the reference laboratory DST, 394 (62.2%) strains were pan-susceptible, 45 (7.1%) 
mono-resistant, 163 (25.7%) multidrug-resistant (MDR-TB), and 30 (4.7%) had pre-
extensive or extensive drug resistance (pre-XDR/XDR-TB). Results of reference and 
local laboratories were discordant in 121 (19.1%) cases. Overall, sensitivity and 
specificity to detect any resistance were 90.8% and 84.3%, respectively. Mortality 
ranged from 6.0% (20/336) in patients with pan-susceptible tuberculosis treated 
according to WHO guidelines to 57.1% (8/14) in patients with resistant strains who were 
under treated. In logistic regression, compared to concordant DST results, the adjusted 
odds ratio of death was 7.33 (95% CI 2.70-19.95) for patients with discordant results 
potentially leading to under treatment.  
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Interpretation: Inaccurate DST by comparison to a reference standard led to under 
treatment of drug resistant tuberculosis and increased mortality. Rapid molecular DST 
of first- and second-line drugs at diagnosis is required to improve outcomes in patients 
with MDR-TB and pre-XDR/XDR-TB. 
 
Funding: National Institutes of Allergy and Infectious Diseases, Swiss National Science 
Foundation, Swiss National Center for Mycobacteria.  
 
Key words: Tuberculosis, drug resistance, MDR-TB, XDR-TB, mortality, treatment 
success, low- and middle-income countries. 
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RESEARCH IN CONTEXT 
Evidence before this study 
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis 
(XDR-TB) are serious threats to the World Health Organization’s End-TB strategy, due 
to limited access to rapid drug resistance identification and appropriate treatment for 
patients with MDR-TB or XDR-TB in many high tuberculosis burden countries. We 
searched PubMed for systematic reviews and original research articles published in any 
language up to March 31, 2018. We combined terms for “tuberculosis”, “drug resistance 
testing”, and “mortality”. Several individual studies and systematic reviews have 
documented the poor outcomes of MDR-TB and pre-XDR/XDR-TB in high-burden 
countries. Two Cochrane reviews evaluated the accuracy of molecular tests detecting 
specific mutations associated with resistance, for example the Xpert MTB/RIF, which is 
recommended by the World Health Organization to detect rifampicin resistance directly 
from sputum.  
Added value of this study 
To our knowledge, this is the first multi-country study assessing the accuracy of drug 
susceptibility testing (DST) in routine settings in high-burden countries by comparing 
local DST results with those from a tuberculosis reference laboratory, and assessing the 
impact on mortality. The study showed that the accuracy of local DST to detect any 
resistance in high-burden countries was moderate (sensitivity 90.8%, specificity 84.3%). 
Results from the reference and local laboratories were discordant in about 20% of 
patients. Mortality during treatment was increased almost two-fold in patients with 
discordant DST results compared to patients with concordant results. Mortality ranged 
from 6.0% in adequately treated patients with pan-susceptible strains to 53.3% in 
inadequately treated patients with drug-resistant strains. In multivariable analyses, 
associations with mortality changed little after adjustment for sex, age, sputum 
microscopy result and HIV status. Of note, HIV infection was not associated with 
mortality during tuberculosis treatment.  
Implications of all the available evidence 
Drug-resistant tuberculosis is difficult to diagnose and to treat, particularly in high-
burden settings, where resources are limited. In these settings, inaccurate DST leading 
to inappropriate treatment contributes to the high mortality associated with drug-
resistant tuberculosis. Local access to accurate and rapid DST of first- and second-line 
drugs is required to improve outcomes in patients with MDR-TB and pre-XDR/XDR-TB. 
Whole genome sequencing is the most promising approach to reach this goal, but much 
work remains to be done to make this approach feasible and affordable in high-burden 
countries.  
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INTRODUCTION 
 
Tuberculosis is a global public health concern. In 2016, an estimated 10.4 million 
individuals developed active tuberculosis worldwide, of whom an estimated 1.0 million 
(10%) were HIV-positive 1. The scale-up of antiretroviral combination therapy (ART) has 
substantially improved the prognosis of HIV-positive patients 2,3, and reduced the 
incidence of tuberculosis in this population 4,5. However, the risk of tuberculosis among 
HIV-positive patients on ART remains four times higher than among HIV-negative 
patients 6.  
The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively 
drug-resistant tuberculosis (XDR-TB) is another threat to the control of tuberculosis 7–9. 
In 2016, it was estimated that 4% of the new patients and 19% (up to 48% in Eastern 
Europe) of previously treated patients had MDR-TB 1. Treatment of MDR-TB and XDR-
TB is challenging due to the longer treatment duration, adverse effects and lower 
efficacy of second-line drugs 10,11. Strategies to prevent drug-resistant tuberculosis 
include monitoring of the prevalence of MDR-TB, wide-spread drug susceptibility testing 
(DST) and ensuring rapid initiation and completion of full courses of effective treatment 
regimens 12,13. Culture-based phenotypic DST is considered the gold-standard, but is 
time and resource intensive, and too slow to influence decisions on starting treatment 
14. Molecular-based resistance testing offers an alternative to culture-based DST 15. 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) detects resistance to rifampicin directly 
from sputum and provides results within 1.5 hours 16, while line-probe assays (LPAs) 
from sputum detect resistance to isoniazid, rifampicin, ethambutol, fluoroquinolones, or 
second-line injectable drugs (amikacin, capreomycin, or kanamycin)  and provide 
results within 1-2 days 15.  
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We compared the results of resistance testing performed locally in ART and 
tuberculosis programmes in high tuberculosis burden countries to those from gold 
standard phenotypic DST performed in the Swiss reference laboratory, and examined 
mortality in HIV-positive and HIV-negative tuberculosis patients with concordant and 
discordant test results. 
 
  
8 
 
METHODS 
This multi-centric cohort study is part of a larger research project on the evolution of 
drug-resistant Mycobacterium tuberculosis (M. tuberculosis) in the context of HIV co-
infection within the International Epidemiology Databases to Evaluate AIDS (IeDEA), a 
global network of ART programs (see www.iedea.org) 17,18. Isolates and clinical data 
were collected from tuberculosis patients in seven high-burden countries in sub-
Saharan Africa, Asia and Latin America. The sample size was calculated so that the 
study had adequate power to detect differences in the prevalence of drug resistance 
between HIV-positive and HIV-negative patients. 
Patient recruitment and data collection  
We included adult patients aged 16 years or older who were treated for active pulmonary 
tuberculosis in Côte d’Ivoire, Democratic Republic of the Congo (DRC), Kenya, Nigeria, 
South Africa, Peru, and Thailand. All seven countries are defined by the World Health 
Organization (WHO) as high tuberculosis burden countries, and DRC, Kenya, Nigeria 
South Africa and Thailand are also high MDR-TB burden and high HIV/tuberculosis 
burden countries 19.  
HIV-positive tuberculosis patients were recruited prospectively from ART clinics 
participating in IeDEA, HIV-negative patients from tuberculosis clinics serving the same 
population. In South Africa, patients included came from well-documented strain 
collections held at the University of Cape Town. Sites were asked to contribute 
pulmonary pre-treatment M. tuberculosis isolates from 25 or more patients within each of 
the four strata defined by HIV status (positive or negative) and drug resistance (MDR or 
pan-susceptible), for a total of 100 patients per site. Supplemental Table S1 summarizes 
the characteristics of participating sites. Patient characteristics were entered online in 
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French or English at baseline, using the Research Electronic Data Capture (REDCap) 
tool 20, including site, type of TB patient as defined by WHO, age, sex, HIV status, CD4 
cell count at start of tuberculosis treatment (if HIV positive), sputum smear microscopy 
result and risk factors for tuberculosis. Treatment regimens were updated and outcomes 
entered during regular follow-up visits. 
Outcomes  
Treatment outcomes were defined according to WHO as cured, treatment completed, 
treatment failure, death, lost to follow-up, transferred to other clinics, ongoing treatment 
at the time of evaluation or unknown treatment outcome 21. “Treatment success” included 
cured patients and patients who completed treatment 21. The main outcome for this study 
was mortality during tuberculosis treatment. Outcome data received up to March 31, 
2018 were included in analyses. 
Drug susceptibility testing 
DST was performed locally using liquid or solid cultures or molecular methods: Xpert 
MTB/RIF or LPAs, such as Genotype MTBDRplus or MTBDRsl tests (Hain Lifesciences, 
Germany).  The reference laboratory of the Swiss National Center for Mycobacteria, 
Zurich, Switzerland performed DST using the Mycobacteria Growth Indicator Tube liquid 
medium system (MGIT, Becton Dickinson, USA) with the following drug concentrations: 
0.1  mg/L for isoniazid, 1.0  mg/L for rifampicin, 100.0  mg/L for pyrazinamide, 5.0  mg/L 
for ethambutol, 1.0  mg/L for amikacin and 0.25  mg/L for moxifloxacin, in line with the 
critical concentrations recently published by WHO 22.  
WHO defines mono-resistance as resistance to one first-line anti-tuberculosis drug 
(isoniazid, rifampicin, pyrazinamide, or ethambutol); MDR as resistance to isoniazid and 
rifampicin; pre-XDR as MDR with additional resistance to any fluoroquinolone or one of 
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the second-line injectable drugs (amikacin, capreomycin, or kanamycin); XDR as MDR 
with additional resistances to any fluoroquinolone and at least one of the second-line 
injectable drugs 21. The category “other” drug resistance included any other combination. 
We defined “pan-susceptible” tuberculosis as no resistance against the six drugs tested 
at the reference laboratory and any resistance as resistance against at least one of the 
tested drugs. First-line regimens (standard treatment) included first-line anti-tuberculosis 
drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol) and second-line regimens 
included a combination of first-line and second-line drugs 21,23. 
Exposure definition and data analysis 
We calculated test accuracy statistics for the diagnosis of any drug resistance. We 
further classified comparisons between the phenotypic and molecular DST results 
obtained in the local laboratories and the reference laboratory as follow: concordant 
results, discordance potentially leading to under treatment, discordance potentially 
leading to over treatment, and other discordant results. We defined drug regimens 
received by patients as compatible with the WHO guidelines in place during the study 
period, as under treatment or as over treatment, based on the reference DST results. 
First-line regimens for pan-susceptible tuberculosis, first or second line-regimens 
prescribed to isoniazid mono-resistant patients, second line-regimens prescribed to 
rifampicin mono-resistant patients, MDR-TB and pre-XDR/XDR-TB patients were 
classified as in accordance with WHO guidelines. Under treatment included first-line 
regimens given to rifampicin mono-resistant patients, MDR-TB and pre-XDR/XDR-TB 
patients, and over treatment second-line regimens given to pan-susceptible tuberculosis 
patients. Supplemental Table S2 shows the classification of regimens. 
We used descriptive statistics to describe patient characteristics by levels of drug 
resistance based on DST performed at the reference laboratory and by HIV status. We 
11 
 
examined determinants of mortality in multivariate logistic regression models. Patients 
with unknown or missing treatment outcome, ongoing treatment, missing treatment 
regimen, missing sputum microscopy and “other” drug-resistant tuberculosis were 
excluded from logistic regression analyses. Logistic models were adjusted for age, sex, 
sputum microscopy result and HIV status. We stratified models by study site by 
including an indicator variable for all sites except South Africa (the reference group). We 
calculated the population attributable fraction of mortality due to discordant DST results 
based on the adjusted model as described by Greenland and Drescher 24. 
Other variables, for example smoking history, diabetes, substance abuse and 
contact to other tuberculosis patients worsened the fit of the model. For HIV-positive 
individuals, models were additionally adjusted for CD4 cell count at tuberculosis 
treatment start. All analyses were done using STATA version 15 (Stata Corporation, 
College Station, Texas, USA). 
Ethical statement 
Local institutional review boards or ethics committees approved the study at all 
participating sites. Informed consent was obtained where requested per local 
regulations. The study was also approved by the Cantonal Ethics Committee in Bern, 
Switzerland. 
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access to 
all the data in the study and had final responsibility for the decision to submit for 
publication. 
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RESULTS 
We obtained M. tuberculosis isolates from 871 patients diagnosed between 2013 and 
2016. We excluded 237 patients from analyses of the accuracy of DST, mainly because 
isolates were contaminated or not viable, and a further 61 patients from analyses of 
mortality, mainly because treatment was ongoing or outcomes unknown at the time of 
closing the database (supplementary Figure S1). Excluded patients were similar in 
terms of age, sex, HIV status, site of tuberculosis, but had lower CD4 counts and were 
more likely to be patients with recurrent tuberculosis and treatment after failure or 
default (supplementary Table S3).  
Characteristics of patients and isolates 
The median age of the 634 included TB patients was 33.2 years (interquartile range 
[IQR] 26.9-42.5 years); 239 (37.7%) were female. The reference laboratory identified 
394 (62.1%) pan-susceptible M. tuberculosis strains, 45 (7.1%) mono-resistant strains, 
163 (25.7%) MDR strains, 30 (4.7%) pre-XDR/XDR strains, and 2 (0.3%) strains with 
other drug resistance profiles (Table 1). Among the 163 patients with MDR-TB, 85 
(52.1%) had resistance to rifampicin and isoniazid only, while the remaining patients 
were additionally resistant to pyrazinamide and/or ethambutol. Among the 24 patients 
with pre-XDR-TB, resistance to moxifloxacin (n=15) was more frequent than resistance 
to amikacin (n=9; Table 2). Patients with resistant strains were more likely to receive 
second-line tuberculosis treatment, and to experience unfavourable treatment outcomes 
than patients with pan-susceptible strains (Table 1).  
A total of 272 (42.9%) tuberculosis patients were HIV-positive, with a median 
CD4 cell count at the start of tuberculosis treatment of 192 cells/µl (IQR 77.5-369 
cells/µl). Among them, 175 (64.3%) were either on ART at the start of tuberculosis 
treatment or initiated ART within 3 months; the ART status of the remaining patients 
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was unknown. Compared to HIV-negative individuals, HIV-positive patients were more 
likely to be female, more likely to have both pulmonary and extrapulmonary disease, 
and more likely to be patients with recurrent tuberculosis (supplemental Table S4). HIV-
positive patients were also more likely to have a negative sputum smear microscopy 
result and more likely to have a pan-susceptible M. tuberculosis infection than HIV-
negative patients. 
Drug susceptibility testing and treatments  
Local laboratories used the Xpert MTB/RIF system, culture, LPAs, or a combination of 
these methods to diagnose drug-resistant infections and inform treatment regimens 
(Table 3, supplemental Table S2). Among the 27 isolates assessed by a combination of 
tests, Xpert MTB/RIF and LPA were used in 17 (63.0%) isolates, Xpert MTB/RIF and 
culture in 8 (29.6%), culture and LPA in one, and Xpert MTB/RIF, culture and LPA in 
another isolate.  
Comparing local with reference laboratory results for any resistance, there were 
218 true and 62 false positives and 332 true and 22 false negatives, for an overall 
sensitivity and specificity of 90.8% (95% CI 87.2-94.5) and 84.3% (80.7-87.9), 
respectively. Sensitivities and specificities were 79.5% (68.4-88.0) and 97.1% (93.4-
99.1) for Xpert MTB/RIF, 93.1% (84.5-97.7) and 71.6% (63.4-78.9) for culture, 100% 
(71.5-100) and 25.0% (0.63-80.6) for LPA and 98.8% (93.4-99.9) and 27.8% (9.7-
53.5%) for combinations of tests. Considering four categories of drug resistance 
(rifampicin mono-resistance, isoniazid mono-resistance, MDR, pre-XDR/XDR), results 
from the reference laboratory and local laboratories were concordant for 513 of 634 
(80.9%) and discordant for 121 of 634 (19.1%) patients. The proportions with 
concordant test results were 88.2% (216 of 245), 72.3% (154 of 213), 73.3% (11 of 15) 
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and 73.0% (73 of 100) for Xpert MTB/RIF, culture, LPA, or a combination of tests, 
respectively (P<0.001).  
There were 23 of 634 (3.6%) discrepancies potentially leading to under 
treatment, 67 of 634 (10.6%) discordant results potentially leading to over treatment, 
and 31 of 634 (4.9%) other discordances (Table 3, supplementary Table S2). When 
analysing the treatments received, they were compatible with WHO guidelines in 491 of 
507 (96.8%) patients with concordant DST results compared to 94 of 121 patients 
(77.7%) with discordant results (P<0.001).  
Mortality  
After excluding 61 of 634 (9.6%) patients with unknown treatment outcomes, missing 
data or “other” drug resistance (supplementary Figure S1), mortality ranged from 5.6% 
(17 of 302) among patients with pan-susceptible strains and concordant DST results to 
44.4% (8 of 18) among patients with pre-XDR/XDR tuberculosis and discordant DST 
results (Table 4). It ranged from 9.8% (6 of 61) in patients with discordant results 
potentially leading to over treatment to 40.9% (9 of 22) in in patients with discordant 
results potentially leading to under treatment (Figure 1, Table 5). Mortality ranged from 
6.4% (23 of 359) in patients with pan-susceptible strains to 34.5% (10 of 29) in patients 
with pre-XDR/XDR tuberculosis. Mortality was higher in patients with isoniazid mono-
resistant strains (7 of 23, 30.4%) than in patients with rifampicin mono-resistant strains 
(2 of 14, 14.3%) but the difference was not statistically significant (P=0.38, Table 4) and 
the two categories were combined in further analyses. Finally, mortality ranged from 
6.0% (20 of 336) in patients with pan-susceptible tuberculosis treated according to 
WHO guidelines to 57.1% (8 of 14) in patients with resistant strains who were under 
treated (Figure 1, Table 5).  
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In multivariable logistic models adjusted for sex, age, sputum microscopy result 
and HIV status, discordant DST results continued to be associated with increased 
mortality compared to concordant DST results (Table 5). Compared to concordant DST 
results, the adjusted odds ratio (aOR) of death was 7.33 (95% CI 2.70-19.95) for 
patients with discordant results potentially leading to under treatment. The population 
attributable fraction associated with any type of discordance obtained from the logistic 
model was 15.15% (95% CI 2·08–26%). 
Drug resistance was associated with higher mortality compared to pan-
susceptible tuberculosis. The aOR was 5.06 (95% Cl 2.74-9.35) for any type of drug 
resistance, and 15.19 (95% 5.54-42.36) for pre-XDR/XDR (Table 5). Finally, compared 
to patients treated according to WHO guidelines with pan-susceptible strains, the aOR 
for death was 4.66 (95% CI 2.38-9.14) for adequately treated patients with resistant 
strains and 19.32 (95% CI 5.59-66.73) for patients with resistant strains receiving 
inadequate regimens (Table 5). Of note, patients with pan-susceptible tuberculosis who 
were over treated also had an increased risk of death: the aOR compared to patients 
with pan-susceptible tuberculosis treated according to WHO guidelines was 3.31 (0.82-
13.45, P=0.10). Sex, positive sputum smear microscopy and HIV status were not 
associated with the odds of death. The results from univariable models were similar to 
the aOR from multivariable models (Table S5). When restricting the analysis to HIV-
positive patients, mortality was higher among patients with CD4 cell counts <50 
cells/µL: the aOR was 6.89 (95% CI 1.57-30.26) compared to patients with higher CD4 
counts at tuberculosis treatment start.  
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DISCUSSION 
 
This study of patients treated for drug-resistant or drug-susceptible tuberculosis in 
seven high tuberculosis burden countries showed that the accuracy of DST testing in 
routine care was moderate, with discordant results from local DST compared to 
phenotypic DST in a reference laboratory in about 20 percent of patients. Discordant 
results led to inadequate treatment and contributed to the excess mortality associated 
with drug-resistant tuberculosis. As expected, mortality was highest in patients with pre-
XDR/XDR tuberculosis and higher in patients who were under treated. Interestingly, 
patients with pan-susceptible tuberculosis who were over treated also had higher 
mortality, although the difference failed to reach conventional levels of statistical 
significance. It is possible that over treated patients had worse adherence and were at 
higher risk of adverse drug effects. To our knowledge, this is the first study to assess 
the accuracy of DST in real world, routine settings and to examine the impact of 
inaccurate results on mortality. Our findings support the recent call for a precision 
medicine approach to the treatment of drug-resistant tuberculosis, guided by detailed 
molecular DST done locally, to replace the standardised, empirical combination 
regimens used in many high tuberculosis burden low- and middle-income countries 25.  
At present, WHO recommends that “Xpert MTB/RIF should be used as the initial 
diagnostic test in individuals suspected of having MDR-TB or HIV-associated 
tuberculosis” 26, based on a Cochrane review of test accuracy studies in adults with 
suspected rifampicin-resistance or MDR-TB 27. In line with this recommendation, Xpert 
MTB/RIF was the most commonly used test in our study sites. The Cochrane review 
reported a pooled sensitivity of 95%, based on 17 studies and 555 patients with 
rifampicin-resistant strains 27. The pooled specificity was 98%. We examined accuracy 
of DST strategies at the level of the local laboratories in high-burden countries, in 
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routine care settings, rather than by evaluating a single test. Our estimates of sensitivity 
and specificity, for the detection of any drug resistance, were lower overall (90.8% and 
84.3%, respectively), and lower for Xpert MTB/RIF (79.5% and 97.1%) and for culture 
(93.1% and 71.6%), indicating that DST is less accurate in routine settings than in test 
accuracy studies 27.  
There are concerns both about false-negative and false-positive Xpert MTB/RIF 
test results, and a policy of confirmatory testing has been introduced in South Africa and 
Brazil 28,29. The discordant DST results that potentially led to under treatment of drug-
resistant tuberculosis (false negative for resistance) were mainly based on locally 
performed cultures, Xpert MTB/RIF tests, or a combination of the two. Of note, the 
recently developed Xpert MTB/RIF Ultra assay has been shown to improve detection of 
rifampicin resistance 30. Culture-based tests dominated discordance that potentially led 
to over treatment, while Xpert MTB/RIF dominated in the category of discordance with 
unclear clinical significance. We acknowledge that some discordance could be 
explained by mixed infections, heteroresistance, or minority resistant populations 31,32.  
LPAs were rarely used in our study, possibly because they have been widely 
replaced by Xpert MTB/RIF, which is easier to use and provides results in a shorter 
time. In addition, LPA suffer from suboptimal accuracy for isoniazid resistance, and 
WHO recommends that culture-based DST for isoniazid should still be used, particularly 
in patients with suspected MDR-TB where the LPA result does not detect isoniazid 
resistance 33. In one case, the local laboratory detected resistance to ethambutol but 
this could not be confirmed in the reference laboratory: DST is challenging for 
ethambutol and less reproducible 34.  
Data on treatment outcomes in drug-resistant tuberculosis are scarce, particularly 
for sub-Saharan Africa. A recent systematic review of treatment outcomes in MDR-TB 
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included data on mortality among adults from seven studies from sub-Saharan Africa, 
six from South Africa and one from Lesotho 35. In these studies, mortality during 
tuberculosis treatment ranged from 12.4% in patients with MDR-TB treated in a referral 
hospital in the Western Cape, South Africa 36, to 45.8% in a study of XDR-TB patients 
from three South African provinces 37. Our results extend these data to other countries 
in the region, and add further data for Peru and Thailand.  
Our study confirms the poor outcome in patients with isoniazid mono-resistant 
tuberculosis who are treated with first-line regimens (as recommended by WHO during 
the study period 38), in line with a study from Durban, South Africa 39 and a recent 
systemic review and meta-analysis 40.  Mortality in mono-resistant tuberculosis patients 
was higher than in MDR-TB patients, especially in isoniazid mono-resistant 
tuberculosis. This might be due to the treatment of almost all isoniazid mono-resistant 
tuberculosis patients with first-line regimens, whereas most MDR-TB patients received 
second-line treatment. Of note, WHO recently updated its guidelines recommending the 
inclusion of fluoroquinolones in the treatment of isoniazid mono-resistant tuberculosis 41. 
Chance is another explanation: there were only few patients with mono-resistant 
tuberculosis and the analysis of mortality, the confidence intervals of the odds ratios for 
mono-resistant and MDR tuberculosis overlapped widely (Table 5). 
In patients co-infected by HIV, the treatment of drug-resistant tuberculosis is 
challenging for several reasons, including the poorer absorption of drugs 42, the risk of 
the immune reconstitution inflammatory syndrome (IRIS) 43, or interactions between 
antiretroviral and second-line tuberculosis drugs 44–46. In contrast to previous studies 
from South Africa, which reported higher mortality at end of treatment in HIV-positive 
patients with MDR-TB compared to HIV-negative MDR-TB patients 36,47, we found no 
association with HIV infection, although confidence intervals were wide. The median 
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CD4 cell count of HIV-positive patients was considerably higher in our study (192 
cells/µL) than in the South African studies 36,47, which may explain the discrepant 
results. A study from Lesotho 48 also found little evidence for a difference in mortality 
between HIV-positive patients (median CD4 cell count 185 cells/ µL) and HIV-negative 
patients. Finally, for patients with XDR-TB, treatment outcomes have been uniformly 
poor in previous studies, irrespective of HIV status 37. 
Our study has several limitations. We sampled eligible patients within strata defined 
by drug resistance and HIV infection, and therefore could not estimate the incidence or 
prevalence of drug-resistant tuberculosis in HIV-positive or HIV-negative patients. In 
previous studies, HIV infection has not been consistently associated with drug 
resistance 28, but it is clear that in regions with a high-burden of HIV, the majority of 
patients with MDR-TB will be co-infected with HIV 28. Although we initially exceeded the 
planned sample size, about a quarter of patients had to be excluded from analyses of 
drug susceptibility, mainly due to lack of growth or contamination of cultures, and about 
a third was excluded from the analysis of mortality outcomes, mainly because vital 
status was unknown at database closure. The reference laboratory tested resistance 
against six drugs, and we will have missed resistance against other drugs used, for 
example kanamycin, ethionamide or levofloxacin. Further, the presence of different 
subpopulations of M. tuberculosis in isolates tested at the local sites vs reference 
laboratory might have introduced variability in phenotypic or molecular DST testing 49.  
In conclusion, our study shows that the accuracy of DST testing in routine care in 
high-burden countries was limited and that inaccurate results led to inadequate 
treatment and contributed to the excess mortality associated with drug-resistant 
tuberculosis. Our results support the notion that access to rapid molecular DST of first- 
and second-line drugs at treatment initiation is required to improve outcomes in patients 
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with MDR-TB and pre-XDR/XDR-TB 28. Whole genome sequencing is the most 
promising approach to reach this goal, but much work remains to be done to make this 
approach feasible and affordable in low- and middle-income countries 28. In particular, 
direct testing of sputum samples should become routine to circumvent lengthy 
mycobacterial cultures 40. A standardised approach for the interpretation of drug 
resistance conferring mutations has recently been developed 50. In the meantime, the 
capacity for the phenotypic and molecular DST testing recommended by WHO should 
be increased to ensure the most adequate treatment of drug-resistant tuberculosis in 
these settings. 
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Table 1: Patient characteristics by phenotypic drug resistance profiles obtained at the Swiss National Center for Mycobacteria. 
 Pan-
susceptible 
Any 
resistance 
P-
value 
 Mono-resistance  Poly-resistance 
 INH RIF PZA  MDR Pre-
XDR/XDR 
Other 
Total  394 (100) 240 (100)   29 (100) 14 (100) 2 (100)  163 (100) 30 (100) 2 (100) 
Sex            
 Female 150 (38.1) 89 (37.1) 0.80  6 (20.7) 3 (21.4) 0  65 (39.9) 14 (46.7) 1 (50.0) 
 Male 244 (61.9) 151 (62.9)   23 (79.3) 11 (78.6) 2 (100)  98 (60.1) 16 (53.3) 1 (50.0) 
Age (year) 34.6  
(27.8-44.6) 
31.5  
(25.3-40.2) 
0.003  34.3  
(26.5-43.2) 
27.1  
(24.9-35.5) 
26.1  
(23.3-28.9) 
 31.5  
(25.4-41.4) 
30.3  
(24.2-37.5) 
27.3  
(24.4-30.2) 
HIV status            
 Negative  200 (50.8) 162 (67.5) <0.001  20 (69.0) 8 (57.1) 1 (50.0)  114 (69.9) 18 (60.0) 1 (50.0) 
 Positive 194 (49.2) 78 (32.5)   9 (31.0) 6 (42.9) 1 (50.0)  49 (30.1) 12 (40.0) 1 (50.0) 
CD4 count at baselinecells/µl 215  
(85-369) 
161  
(61-369) 
 0.79  92.5  
(55-161) 
63.5  
(43-81) 
43  259  
(151-528) 
32  
(5-105) 
213 
No. of observations (%) 155 (39.3) 45 (18.9)   6 (20.7) 6 (42.9) 1 (50.0)  24 (14.7) 7 (23.3) 1 (50.0) 
Treatment regimen             
 First line 369 (93.7) 46 (19.2) <0.001  27 (93.1) 0 2 (5.4)  14 (9.2) 2 (6.7) 1 (50.0) 
 Second line  25 (6.3) 188 (78.3)   2 (6.9) 14 (100) 0  143 (85.3) 28 (93.3) 1 (50.0) 
 Unknown 0 6 (2.5)   0 0 0  6 (5.5) 0 0 
Treatment outcomes             
 Success 287 (72.8) 124 (51.7) <0.001  15 (51.7) 7 (50.0) 0  88 (54.0) 13 (43.3) 1 (50.0) 
 Mortality 24 (6.1) 45 (18.8)   7 (24.1) 2 (14.3) 1 (50.0)  24 (14.7) 10 (33.3) 1 (50.0) 
 Treatment failure 12 (3.0) 10 (4.2)   0 0 1 (50.0)  5 (3.1) 4 (13.3) 0 
 Lost to follow-up  29 (7.4) 30 (12.5)   1 (3.5) 3 (21.4) 0  26 (16.0) 0 0 
 Transfer 15 (3.8) 14 (5.8)    0 2 (14.3) 0  9 (5.5) 3 (10.0) 0 
 Ongoing treatment / unknown 27 (6.9) 17 (7.1)   6 (20.7) 0 0  11 (6.7) 0  0 
Country             
 Côte d’Ivoire 48 (12.2) 51 (21.3) <0.001  3 (10.3) 0 0  44 (27.0) 4 (13.3) 0 
 Democratic Republic of the Congo 33 (8.4) 29 (12.1)   0 1 (7.1) 0  19 (11.7) 9 (30.0) 0 
 Kenya 24 (6.1) 11 (4.6)   2 (6.9) 1 (7.1) 0  8 (4.9) 0 0 
 Nigeria 20 (5.1) 36 (15.0)   1 (3.5) 5 (35.7) 0  26 (16.0) 4 (13.3) 0 
 Peru 66 (16.8) 38 (15.8)   8 (27.6) 0 0  27 (16.6) 3 (10.0) 0 
 South Africa 130 (33.0) 57 (23.8)   6 (20.7) 7 (50.0) 1 (50.0)  32 (15.5) 10 (33.3) 1 (50.0) 
 Thailand 73 (18.5) 18 (7.5)   9 (31.0) 0 1 (50.0)  7 (4.3) 0 1 (50.0) 
Analysis based on 634 patients (see supplementary Figure S1). Numbers (%) or median (interquartile range) are shown.  
INH, isoniazid; MDR, multidrug resistant; PZA, pyrazinamide; RIF, rifampicin; XDR, extensively drug resistant.
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Table 2: Drug resistance profiles identified at the Swiss National Center for Mycobacteria.  
 
Resistance profiles No. of patients 
 (n=634) 
Pan-susceptible 394 (62.2%) 
Mono-resistance 45 (7.1%) 
INH mono-resistance 29 
RIF mono-resistance 14 
PZA mono-resistance 2 
MDR 163 (25.7%) 
INH+RIF 85 
INH+RIF+EMB 11 
INH+RIF+PZA 47 
INH+RIF+EMB+PZA 20 
Pre-XDR 24 (3.2%) 
INH+RIF +MOX+EMB+PZA 8 
INH+RIF +MOX+EMB 1 
INH+RIF +MOX+PZA 4 
INH+RIF +MOX 2 
INH+RIF +AMK+PZA+EMB 4 
INH+RIF +AMK+PZA 4 
INH+RIF +AMK 1 
XDR 6 (0.8%) 
INH+RIF +AMK+MOX+EMB 3 
INH+RIF +AMK+MOX+PZA 2 
INH+RIF +AMK+MOX 1 
Other 2 (0.3%) 
INH+MOX 1 
INH+PZA 1 
 
Analysis based on 634 patients (see supplementary Figure S1).  
 
AMK, amikacin; EMB, ethambutol; INH, isoniazid; MDR, multidrug resistant; MOX, moxifloxacin; PZA, pyrazinamide; RIF, 
rifampicin; XDR, extensively drug resistant. 
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Table 3: Concordance and discordance of drug susceptibility results obtained from reference and local laboratories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis based on 634 patients (see supplementary Figure S1). Number of patients (%) are shown.  
DST, drug susceptibility testing; EMB, ethambutol; INH, isoniazid; LPA, line probe assay; MDR, multidrug resistance; PZA, pyrazinamide; RIF, rifampicin; SM, streptomycin; XDR, extensively 
drug resistant.  
In some patients the test used to diagnose drug-resistant infection at the local laboratories was unknown. Therefore, numbers do not always add up to the row totals. 
a
 RIF resistance diagnosed with Xpert MTB/RIF was classified as MDR. 
b
 Twenty-one strains were resistant to EMB, ten to SM and two INH. 
c
 Five strains were resistant to INH. 
d
 Fifteen strains were resistant to INH, two to PZA 
 
  
 
Concordance/ 
discordance of 
DST results 
 DST results by laboratory  Total  Test used at local laboratories 
 
Reference laboratory 
(phenotypic) 
Local laboratories  (n=634)  
Xpert 
MTB/RIF
a Culture LPA 
Combination 
of tests 
Concordance 
 Pan-susceptible Pan-susceptible  332 (64.7)  167 (77.3) 101 (65.6) 1 (9.1) 5 (6.8) 
 RIF mono-resistance RIF mono-resistance  8 (1.6)  0 0 0 7 (9.6) 
 INH mono-resistance INH mono-resistance  8 (1.6)  0 8 (5.2) 0 0 
 MDR MDR  153 (29.8)  49 (22.7) 44 (28.6) 8 (72.7) 52 (71.2) 
 Pre-XDR and XDR Pre-XDR and XDR  12 (2.3)  0 1 (0.6) 2 (18.2) 9 (12.3) 
 Total   513 (100)  216 (100) 154 (100) 11 (100) 73 (100) 
Discordance 
potentially 
leading to under 
treatment 
 MDR Pan-susceptible  5 (21.7)  2 (25.0) 2 (22.2) 0 1 (16.7) 
 Pre-XDR and XDR MDR  18 (78.3)  6 (75.0) 7 (77.8) 0 5 (83.3) 
 
Total   23 (100)  8 (100) 9 (100) 0 6 (100) 
Discordance 
potentially 
leading to over 
treatment 
 Pan-susceptible RIF mono-resistance  14 (20.9)  0 0 3 (100) 10 (71.4) 
 Pan-susceptible MDR  14 (20.9)  3 (60.0) 8 (18.2) 0 3 (21.4) 
 Pan-susceptible Other mono-resistance
b 
 33 (49.3)  2 (40.0) 31 (70.5) 0 0  
 Other mono-resistance
c
 MDR  5 (7.5)  0 5 (11.4) 0 0 
 MDR Pre-XDR or XDR  1 (1.5)  0 0 0 1 (7.1) 
 Total   67 (100)  5 (100) 44 (100) 3 (100) 14 (100) 
Other 
discordance  
 Pan-susceptible EMB, SM  1 (3.2)  0 1 (16.7) 0 0 
 RIF mono-resistance MDR  7 (22.6)  2 (12.5) 0 0 5 (28.6) 
 Other mono-resistance
d
 Pan-susceptible  17 (54.8)  13 (81.3) 3 (50.0) 0 0 
 INH, MOX Mono-resistance  1 (3.2)  0 1 (16.7) 0 0 
 IHN, PZA MDR  1 (3.2)  0 1 (16.7) 0 0 
 MDR RIF mono-resistance  3 (9.7)  0 0 1 (100) 2 (71.4) 
 MDR EMB, SM  1 (3.2)  1 (6.2) 0 0 0 
 Total   31 (100  16 (100) 6 (100) 1 (100) 7 (100) 
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Table 4: Mortality by phenotypic drug resistance profiles obtained at the Swiss National 
Centre for Mycobacteria and by concordance with local results. 
 
  Concordant 
results 
Discordant 
results 
 Total 
   
Pan-susceptible 17/302 (5.6%) 6/57 (10.5%)  23/359 (6.4%) 
Any resistance 29/164 (17.7%) 15/50 (30.0%)  44/214 (20.6%) 
         
Mono-resistance        
    INH 5/8 (62.5%) 2/15 (13.3%)  7/23 (30.4%) 
    RIF 0/7 (0%) 2/7(28.6%)  2/14 (14.3%) 
    PZA - 1/2 (50.0%)  1/2 (50.0%) 
         
Poly-resistance        
   MDR 22/138 (15.9%) 2/8 (25.0%)  24/146 (14.4%) 
   Pre-XDR/XDR 2/11 (18.2%) 8/18 (44.4%)  10/29 (34.5%) 
         
Total 46/466 (9.9%) 21/107 (19.6%)  67/573 (11.7%) 
  
Analysis based on 573 patients with complete data (see supplementary Figure S1).  
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Table 5. Results from logistic regression models of the probability of death during 
tuberculosis treatment. 
 
No. of 
patients 
No. of 
deaths (%) 
Model 1  
aOR (95% CI) 
Model 2  
aOR (95% CI) 
Model 3 
aOR (95% CI) 
      
Concordance / discordance  
of DST results    
 
 
 
   Concordance 466 46 (9.9) 1   
   Discordance potentially  
   leading to under treatment 
22 9 (40.9) 7.33 (2.70-19.95)   
   Discordance potentially  
   leading to over treatment 
61 6 (9.8) 0.81 (0.31-2.11)   
   Other discordance 24 6 (25.0) 4.92 (1.69-14.33)   
      
Drug resistance a 
  
   
   Pan-susceptible  359 23 (6.4)  1  
   Mono-resistance 39 10 (25.6)  6.05 (2.36-15.56)  
   MDR 146 24 (16.4)  3.83 (1.88-7.81)  
   Pre-XDR/XDR 29 10 (34.5)  15.19 (5.45-42.36)  
 
  
 
 
 
Treatment adequacy by 
drug resistance    
 
 
 
   Pan-susceptible, compatible 
   with WHO guidelines 
336 20 (6.0)   1 
   Pan-susceptible, over  
   treatment 
23 3 (13.0)   3.31 (0.82-13.45) 
   Any resistance, compatible 
   with WHO guidelines  
200 36 (18.0)   4.66 (2.16-9.14) 
   Any resistance, under  
   treatment 
14 8 (57.1)   19.32 (5.59-66.73) 
      
Sex 
    
 
   Female 219 20 (9.1) 1 1 1 
   Male 354 47 (13.3) 1.47 (0.81-2.67) 1.42 (0.78-2.60) 1.46 (0.80-2.70) 
   
   
Age (per 1 year increase) 573 67 (11.7) 1.04 (1.01-1.06) 1.04 (1.01-1.06) 1.04 (1.01-1.06) 
   
   
Sputum microscopy 
  
   
   Negative 111 10 (9.0) 1 1 1 
   Positive 462 57 (12.3) 1.14 (0.51-2.56) 1.03 (0.45 -2.37) 0.90 (0.40-2.07) 
   
   
HIV status 
  
   
   Negative 337 43 (12.8) 1 1 1 
   Positive 236 24 (10.2) 0.90 (0.50-1.61) 1.19 (0.65-2.20) 1.19 (0.65-2.20) 
      
Models based on 573 patients with complete data for all variables shown (see supplementary Figure S1).  
Model 1 was adjusted for concordance / discordance of DST results, sex, age, sputum microscopy and HIV status; model 2 was 
adjusted for drug resistance, sex, age, sputum microscopy and HIV status; model 3 was adjusted for treatment adequacy, sex, age, 
sputum microscopy and HIV status. 
Abbreviations: DST, drug susceptibility testing; MDR, multidrug resistant; XDR, extensively drug-resistant 
a
 Results from the Swiss National Reference Center for Mycobacteria 
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Figure 1: Mortality according to drug resistance, to concordance or discordance of drug 
susceptibility testing (DST) results and to treatment adequacy. Error bars are standard errors. 
All P values <0.001 for difference in mortality across categories. Analysis based on 573 patients with 
complete data. 
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Supplemental Figure S1: Selection of the study population.  
 
 
 
  
Data received as of  
March 30, 2018 
n=871 
Exclusions (n=237): 
- No growth / contamination (n=218) 
- Age <16 years or unknown (n=11) 
- HIV status unknown (n=4) 
- Extrapulmonary tuberculosis (n=4) 
Included in analyses of 
accuracy of Drug Susceptibility 
Testing (DST) 
n=634 
Exclusions (n=61): 
- Ongoing or unknown treatment outcomes 
(n=44) 
- Missing data on smear microscopy result 
(n=9) 
- Missing data on treatment regimen (n=6) 
- “Other” drug resistant tuberculosis (n=2) 
Included in logistic regression 
models of the probability of 
death 
n=573 
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Table S1: Characteristics of participating study sites and settings. 
MGIT, Mycobacteria Growth Indicator Tube; MDR, multidrug resistant; RR rifampicin resistant; TB, tuberculosis; 
a 
per 100,000 population (from Global Tuberculosis Report 2017. Geneva: World Health Organization, 2017)
 Côte d’Ivoire Nigeria Democratic 
Republic of the 
Congo 
Kenya South Africa Peru Thailand 
Study sites        
 Location  Abidjan Zaria Kinshasa Eldoret Khayelitsha, Cape 
Town 
Lima Bangkok 
 Setting Urban  Rural Urban Rural Urban Urban Urban 
 Recruitment  Centre de Prise en 
charge de 
Recherche et de 
Formation 
(CePReF), and 
affiliated TB clinics 
National TB and 
Leprosy Training 
Center (NTBLTC), 
and affiliated TB 
clinics 
Kalembelembe 
Hospital, ART 
program, and 
affiliated TB clinics 
Academic Model 
Providing Access to 
Healthcare 
(AMPATH), and 
affiliated TB clinics 
Khayelitsha ART 
Program, 
Khayelitsha 
township, and 
affiliated TB clinics 
Instituto de Medicina 
Tropical Alexander von 
Humboldt; Universidad 
Peruana Cayetano 
Heredia, and affiliated 
TB clinics 
HIV Netherlands Australia 
Thailand Research 
Collaboration (HIV-NAT),  
King Chulalongkorn 
Memorial Hospital, and 
affiliated TB clinics 
 Laboratory facilities Centre de 
Diagnostic et de 
Recherche sur le 
Sida (CeDReS) 
NTBLTC National 
TB reference 
laboratory 
National TB 
Laboratory 
Mycobacteriology 
Laboratory at 
AMPATH 
National Health 
Laboratory Service, 
and Molecular 
Biology Laboratory, 
Stellenbosch 
University 
National TB Lab and 
Instituto de Medicina 
Tropical A. von 
Humboldt TB Research 
Laboratory 
HIV-NAT Research 
Laboratory 
 Drug susceptibility  
 testing methods 
Löwenstein-Jensen 
proportion culture 
Xpert MTB/RIF, 
MGIT liquid culture, 
line probe assays 
Xpert MTB/RIF, 
Löwenstein-Jensen 
proportion culture 
Xpert MTB/RIF Xpert MTB/RIF, 
MGIT liquid culture, 
line probe assays 
Löwenstein-Jensen 
proportion method, 
MGIT liquid culture 
MGIT liquid culture 
Country TB statistics        
 Incidence (including HIV)        
 Number (thousands) 36 407 254 169 438 37 119 
 Rate
a
 153 219 323 348 781 117 172 
 Incidence MDR/RR-TB        
 Number (thousands) 2.1 20 7.6 3 19 3.5 4.7 
 Rate
a
 8.9 11 9.7 6.2 34 11 6.8 
 Mortality (HIV-negative  
 and HIV-positive people) 
       
 Number (thousands) 2.8 39 8.5 24 100 0.46 3.9 
 Rate
a
 12 21 11 50 181 1.5 5.7 
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Table S2: Classification of treatment regimens by drug resistance profile.  
Drug resistances 
according to Swiss 
National Center for 
Mycobacteria 
 Total   Compatible with WHO guidelines  Over-treatment    Under-treatment  
    No.   No.  Treatment regimen  No. Treatment regimen   No. Treatment regimen 
Pan-susceptible  394   369 2 INH-RIF-PZA-EMB / 4 INH-RIF  1 2 INH-PZA-EMB-OFX     
        1 2 INH-PZA-EMB-SM-OFX     
        2 2 INH-RIF-PZA-EMB-SM / 1 INH-RIF-PZA-
EMB / 5 INH-RIF-EMB 
    
        2 2 INH-RIF-PZA-EMB / 4 INH -RIF     
        1 6 PZA-EMB-KM / CM-LFX-PTO-CS / 14 
PZA-EMB-LFX-PTO-CS 
    
        3 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
    
        1 PZA-KM-LFX-PTO-CS     
        14 PZA-EMB-KM-ETO-MOX-TRD     
Mono-resistance  45            
INH mono-resistance  29    27 2 INH-RIF-PZA-EMB / 4 INH-RIF         
    1 PZA-EMB-KM-LFX-ETO-CS         
    1 RIF-PZA-EMB-LFX       
RIF mono-resistance  14   7 PZA-EMB-KM-ETO-MOX-TRD         
     3 PZA-KM-LFX-PTO-CS         
     2 PZA-AM-LFX-PTO-CS         
     1 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
         
     1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
PZA mono-resistance  2   2 2 INH-RIF-PZA-EMB / 4 INH-RIF         
            
MDR  163             
INH+RIF  85  2 2 INH-RIF-PZA-EMB-SM / 1 INH-RIF-PZA-
EMB / 5 INH-RIF-EMB 
     10 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
     31 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
     1 6 PZA-EMB-KM / CM-LFX-PTO-CS / 14 PZA-
EMB-LFX-PTO-CS 
        
     4 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
        
     2 PZA-AM-LFX-PTO-CS         
     2 PZA-EMB-KM-CS-ETO-CFX-PAS          
     1 PZA-EMB-KM-ETO-CFX-CS          
     1 PZA-EMB-KM-ETO-LFX-PAS         
    1 PZA-EMB-KM-LFX-CS         
      1 PZA-EMB-KM-LFX-ETO-CS         
     13 PZA-KM-LFX-PTO-CS         
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     1 RIF-PZA-EMB-LFX         
     10 PZA-EMB-KM-ETO-MOX-TRD        
     1 PZA-KM-LFX-ETO-CS-PAS         
INH+RIF+EMB  11   5 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
       1 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
     1 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
        
     1 PZA-KM-LFX-PTO-CS         
     3 PZA-EMB-KM-ETO-MOX-TRD         
INH+RIF+PZA  47  1 2 INH-RIF-PZA-EMB-SM / 1 INH-RIF-PZA-
EMB / 5 INH-RIF-EMB 
      2 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
     17 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
         
     1 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
        
     1 PZA-AM-LFX-PTO-C          
     1 EMB-KM-LFX-ETO-CS         
     3 PZA-EMB-KM-LFX-ETO-CS         
     1 PZA-EMB-LFX-AM-ETO-CS          
     1 INH-PZA-EMB-KM-LFX         
     1 INH-PZA-EMB-CFZ-ETO-KM-LZD-MOX-PAS-
TRD-BDQ-DLM 
        
     4 PZA-KM-LFX-PTO-CS         
     12 PZA-EMB-KM-ETO-MOX-TRD         
     1 PZA-KM-LFX-ETO-CS-PAS         
INH+RIF+EMB+PZA  20   2 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
      1 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
     2 6 PZA-EMB-KM / CM-LFX-PTO-CS / 14 PZA-
EMB-LFX-PTO-CS 
        
     1 8 PZA-KM-PTO-CS-LFX / 12 PZA-PTO-CS-
LFX 
        
     1 PZA-AM-LFX-PTO-CS          
     3 PZA-EMB-KM-LFX-ETO-CS          
     3 PZA-KM-LFX-PTO-CS        
     6 PZA-EMB-KM-ETO-MOX-TRD           
Pre-XDR  24             
INH+RIF +AMK  1   1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
INH+RIF +AMK+PZA  4   1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
     1 PZA-EMB-KM-CS-ETO-CFX-PAS         
     2 Z-CFZ-ETO-KM-LZD-MOX-PAS         
INH+RIF +AMK+PZA+EMB  4   2 Z-CFZ-ETO-KM-LZD-MOX-PAS       1 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
     1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
INH+RIF +MOX  2  1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-         
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PZA-MOX-CFZ 
      1 INH-PZA-EMB-CFZ-ETO-KM-LZD-MOX-PAS-
TRD-BDQ-DLM 
        
INH+RIF +MOX+EMB  1   1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
INH+RIF +MOX+PZA  4   3 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
     1 INH-PZA-EMB-CFZ-ETO-KM-LZD-MOX-PAS-
TRD-BDQ-DLM 
        
               
INH+RIF +MOX+EMB+PZA  8   2 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
        
     2 INH-PZA-EMB-CFZ-ETO-KM-LZD-MOX-PAS-
TRD-BDQ-DLM 
        
     3 PZA-KM-LFX-PTO-CS         
     1 6 PZA-EMB-KM-OFX-PTO-CS  / 18 PZA-EMB-
OFX-PTO-CS 
         
XDR  6           
INH+RIF +AMK+MOX+EMB  3   2 INH-PZA-EMB-CFZ-ETO-KM-LZD-MOX-PAS-
TRD-BDQ-DLM 
        
      1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
         
INH+RIF +AMK+MOX+PZA  2   1 4 INH-PZA-EMB-KM-MOX-PTO-CFZ / 5 EMB-
PZA-MOX-CFZ 
      1 2 INH-RIF-PZA-
EMB / 4 INH-RIF 
INH+RIF +AMK+MOX  1   1 PZA-KM-LFX-PTO-CS         
Other  2             
INH+MOX  1   1 PZA-EMB-KM-ETO-MOX-TRD          
INH+PZA  1   1 2 INH-RIF-PZA-EMB / 4 INH-RIF         
 
 
The treatment regimen was missing in six patients. 
INH, isioniazid; RIF, rifampicin; PZA, pyrazinamide; EMB, ethambutol; SM, streptomycin; KM, kanamycin; AM, amikacin; CM, capreomycin; LFX, levofloxacin; OFX, Ofloxacin; MOX, 
moxifloxacin; ETO, ethionamide; PTO, prothionamide; CS, D-cycloserine; TRD, terizidone; CFZ, clofazimine; LZD, linezolid; BDQ, bedaquiline; DLM, Delamanid; PAS, Para-aminosalicylic acid 
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Table S3: Patient characteristics of included and excluded TB patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers (%) or median (interquartile range) are shown.   
  Excluded patients  Included patients  
    (n=237) (n=634) 
Age (years)   33.3 (26.8-42.0) 33.2 (26.9-42.5) 
- No. of observations (%)  220 (92.8)  
Sex     
 Male  135 (57.0) 395 (62.3) 
 Female   102 (43.0) 239 (37.7) 
HIV      
 Negative   125 (52.7) 362 (57.1) 
 Positive   108 (45.6) 272 
 Unknown   4 (1.7) - 
Site of TB disease      
 Pulmonary   230 (97.1) 609 (96.1) 
 Extrapulmonary   4 (1.7) - 
 Pulmonary and extrapulmonary   1 (0.4) 25 (3.9) 
 Unknown    2 (0.8) - 
CD4 count at baseline (cells/µl)   129 (88-185) 192 (77.5-369)  
 No. of observations (%)   96 (40.5) 200 (73.5) 
Type of TB patient     
 New patient   111 (46.8) 411 (64.8) 
 Recurrent TB   52 (21.9) 120 (18.9) 
 Treatment after failure   42 (17.8) 70 (11.0) 
 Treatment after default   29 (12.2) 27 (4.3) 
 Unknown   3 (1.3) 6 (0.9) 
Sputum smear microscopy     
 Negative   26 (11.0) 113 (17.8) 
 Positive   202 (85.2) 512 (80.8) 
 Unknown    9 (3.8) 9 (1.4) 
TB treatment outcome      
 Success   126 (53.2) 411 (64.8) 
 Cure   71 (30.0) 298 (47.0) 
 Treatment completed   55 (23.2) 113 (17.8) 
 Treatment failure   2 (0.8) 22 (3.5) 
 Death   7 (3.0) 69 (10.9) 
 Lost to follow-up   11 (4.6) 59 (9.3) 
 Transfer   11 (4.6) 29 (4.6) 
 Ongoing treatment    44 (18.6) 4 (0.6) 
 Unknown   36 (15.2) 40 (6.3) 
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Table S4: Patient characteristics by HIV status at diagnosis of tuberculosis.  
  All Patients  HIV-negative HIV-positive p-value 
  (n=634) (n=362) (n=272)  
Age (years) 33.2 (26.9-42.5) 31.7 (25.1-43.3) 34.7 (29.1-42.0) 0.49 
Sex     
 Male 395 (62.3) 249 (69.8) 146 (53.7) <0.001 
 Female 239 (37.7) 113 (31.2) 126 (46.3)  
Site of TB disease    
 Pulmonary 609 (96.1) 355 (98.1) 254 (93.4) 0.003 
 Pulmonary and extrapulmonary 25 (3.9) 7 (1.9) 18 (6.6)  
CD4 count at baseline (cells/µl) - - 192 (77.5-369)  
 No. of observations (%) - - 200 (73.5)  
Type of TB patient   <0.001 
 New patient 411 (64.8) 233 (64.4) 178 (65.4)  
 Recurrent TB 120 (18.9) 56 (15.5) 64 (23.5)  
 Treatment after failure 70 (11.0) 56 (15.5) 14 (5.2)  
 Treatment after default 27 (4.3) 15 (4.1) 12 (4.4)  
 Unknown 6 (0.9) 2 (0.5) 4 (1.5)  
Sputum smear microscopy   <0.001 
 Negative 113 (17.8) 46 (12.7) 67 (24.6)  
 Positive 512 (80.8) 312 (86.2) 200 (73.5)  
 Unknown  9 (1.4) 4 (1.1) 5 (1.8)  
TB drug resistance 
a
  <0.001 
 Pan-susceptible 394 (62.1) 200 (55.2) 194 (71.3)  
 Any resistance 240 (37.9) 162 (44.8) 78 (28.7) <0.001 
  Mono-resistant  45 (7.1) 29 (8.0) 16 (5.9)  
  MDR 163 (25.7) 114 (31.5) 49 (18.0)  
  Pre-XDR / XDR 30 (4.7) 18 (5.0) 12 (4.4)  
  Other 2 (0.3) 1 (0.3) 1 (0.4)  
TB treatment outcome   0.012 
 Success 411 (64.8) 238 (65.7) 173 (63.6)  
o Cure 298 (47.0) 169 (46.7) 129 (47.4)  
o Treatment completed 113 (17.8) 69 (19.1) 44 (16.2)  
 Treatment failure 22 (3.5) 10 (2.8) 12 (4.4)  
 Death 69 (10.9) 43 (11.9) 26 (9.6)  
 Lost to follow-up 59 (9.3) 40 (11.0) 19 (7.0)  
 Transfer 29 (4.6) 17 (4.7) 12 (4.4)  
 Ongoing treatment  4 (0.6) 1 (0.3) 3 (1.1)  
 Unknown 40 (6.3) 13 (3.6) 27 (9.9)  
Country   <0.001 
 Côte d’Ivoire 99 (15.6) 57 (15.7) 42 (15.4)  
 Democratic Republic of the Congo 62 (9.8) 50 (13.8) 12 (4.4)  
 Kenya 35 (5.5) 15 (4.1) 20 (7.4)  
 Nigeria 56 (8.8) 37 (10.2) 19 (7.0)  
 Peru 104 (16.4) 64 (17.7) 40 (14.7)  
 South Africa 187 (29.5) 84 (23.2) 103 (37.9)  
 Thailand 91 (14.4) 55 (15.2) 36 (13.2)  
Analysis based on 634 patients (see supplementary Figure S1). Numbers (%) or median (interquartile range) are 
shown.  
MDR, multidrug resistant; TB, tuberculosis; XDR, extensively drug resistant 
a
 Results from the Swiss National Reference Center for Mycobacteria 
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Table S5. Results from univariable logistic regression models of the probability of death 
during tuberculosis treatment.   
 No. of 
patients 
No. of 
deaths (%) 
Odds ratio  
(95% CI) 
    
Concordance / discordance  
of DST results    
 
   Concordance 466 46 (9.9) 1 
   Discordance potentially  
   leading to under treatment 
22 9 (40.9) 6.32 (2.56-15.59) 
   Discordance potentially  
   leading to over treatment 
61 6 (9.8) 1.00 (0.41-2.44) 
   Other discordance 24 6 (25.0) 3.04 (1.15-8.05) 
    
Drug resistance a    
   Pan-susceptible  359 23 (6.4) 1 
   Mono-resistance 39 10 (25.6) 5.03 (2.19-11.60) 
   MDR 146 24 (16.4) 2.87 (1.56-5.28) 
   Pre-XDR/XDR 29 10 (34.5) 7.69 (3.21-18.44) 
    
Treatment adequacy by 
drug resistance   
 
   Pan-susceptible, compatible 
   with WHO guidelines 
336 20 (6.0) 1 
   Pan-susceptible, over  
   treatment 
23 3 (13.0) 2.37 (0.65-8.65) 
   Any resistance, compatible 
   with WHO guidelines  
200 36 (18.1) 3.49 (1.96-6.18) 
   Any resistance, under  
   treatment 
14 8 (53.3) 21.06 (6.66-66.59) 
    
Sex    
   Female 219 20 (9.1) 1 
   Male 354 47 (13.3) 1.52 (0.88-2.65) 
    
Age (per 1 year increase) 573 67 (11.7) 1.03 (1.01-1.05) 
    
Sputum microscopy    
   Negative 111 10 (9.0) 1 
   Positive 462 57 (12.3) 1.42 (0.70-2.88) 
    
HIV status    
   Negative 337 43 (12.8) 1 
   Positive 236 24 (10.2) 0.77 (0.46-1.31) 
                       
                      Models based on 573 patients with complete data for all variables shown (see supplementary Figure S1).  
        Abbreviations: DST, drug susceptibility testing; MDR, multidrug resistant; XDR, extensively drug-resistant 
           a
 Results from the Swiss National Reference Center for Mycobacteria 
